Reneo Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-2.00 Insider Own1.20% Shs Outstand24.50M Perf Week35.33%
Market Cap114.86M Forward P/E- EPS next Y-2.29 Insider Trans0.00% Shs Float23.73M Perf Month101.37%
Income-49.00M PEG- EPS next Q-0.60 Inst Own75.40% Short Float / Ratio0.40% / 1.73 Perf Quarter166.36%
Sales- P/S- EPS this Y-102.30% Inst Trans0.53% Short Interest0.10M Perf Half Y40.87%
Book/sh4.57 P/B1.28 EPS next Y-5.00% ROA-35.30% Target Price26.33 Perf Year67.91%
Cash/sh5.92 P/C0.99 EPS next 5Y- ROE-37.80% 52W Range1.79 - 6.17 Perf YTD151.50%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-5.02% Beta-
Dividend %- Quick Ratio12.80 Sales past 5Y- Gross Margin- 52W Low227.37% ATR0.45
Employees32 Current Ratio12.80 Sales Q/Q- Oper. Margin- RSI (14)76.25 Volatility12.47% 11.51%
OptionableNo Debt/Eq0.00 EPS Q/Q-1.70% Profit Margin- Rel Volume0.00 Prev Close5.86
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume55.18K Price5.86
Recom1.30 SMA2042.71% SMA5078.38% SMA20097.22% Volume0 Change0.00%
Sep-19-22Resumed H.C. Wainwright Buy $31
Jan-27-22Initiated Robert W. Baird Outperform $28
Dec-21-21Initiated H.C. Wainwright Buy $28
Nov-22-21Initiated Ladenburg Thalmann Buy $45
May-04-21Initiated SVB Leerink Outperform $25
May-04-21Initiated Piper Sandler Overweight $45
May-04-21Initiated Jefferies Buy $24
Mar-14-23 07:30AM
Mar-09-23 08:00AM
Mar-03-23 06:07AM
Feb-02-23 07:35AM
Jan-31-23 07:35AM
07:12AM Loading…
Dec-04-22 07:12AM
Nov-08-22 07:35AM
Nov-03-22 08:00AM
Sep-14-22 06:02AM
Sep-06-22 08:35AM
Aug-29-22 07:35AM
Aug-09-22 08:00AM
Aug-04-22 09:10AM
Aug-02-22 07:30AM
Jul-26-22 09:52AM
07:30AM Loading…
Jul-11-22 08:00AM
Jun-30-22 08:00AM
Jun-20-22 08:33AM
May-10-22 04:05PM
Mar-23-22 04:05PM
Mar-07-22 08:30AM
Feb-02-22 08:00AM
Jan-24-22 08:00AM
Jan-10-22 11:55AM
Dec-22-21 11:04AM
Nov-11-21 04:05PM
Nov-01-21 04:05PM
Oct-14-21 08:00AM
Oct-11-21 02:35PM
08:00AM Loading…
Sep-28-21 08:26AM
Sep-09-21 09:12AM
Aug-11-21 05:55AM
Jul-28-21 08:00AM
Jul-12-21 09:30AM
Jul-09-21 08:00AM
Jul-07-21 08:00AM
Jun-29-21 08:00AM
May-20-21 06:00AM
May-19-21 06:00AM
Apr-13-21 08:14AM
Apr-09-21 12:32PM
Apr-08-21 09:42PM
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. Its lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. The company was incorporated in 2014 and is headquartered in Irvine, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cruse MichaelChief Operating OfficerSep 01Buy3.397,50025,44813,697Sep 02 05:12 PM
GREY MICHAEL GExecutive ChairmanAug 31Option Exercise1.9750,00098,50050,000Sep 02 05:10 PM
Cruse MichaelChief Operating OfficerAug 31Buy3.213,21210,3076,197Aug 31 05:47 PM
Cruse MichaelChief Operating OfficerAug 30Buy3.191,8455,8932,985Aug 31 05:47 PM
Cruse MichaelChief Operating OfficerAug 30Buy3.169753,08131,758Aug 31 05:47 PM
Cruse MichaelChief Operating OfficerAug 29Buy3.241,1403,6941,140Aug 31 05:47 PM
Cruse MichaelChief Operating OfficerAug 29Buy3.248326930,783Aug 31 05:47 PM